2019
|
Sign up to set email alerts
|

Abstract: Aim To evaluate the efficacy and safety of fast‐acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII) in participants with type 1 diabetes (T1D). Materials and Methods This was a double‐blind, treat‐to‐target, randomized, 16‐week trial investigating CSII treatment with faster aspart (n = 236) or IAsp (n = 236). All available information, regardless of treatment discontinuation, was used for the evaluation of effect. Results Faster aspart was non‐… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

7
87
1
4

Year Published

2019
2019
2019
2019

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 46 publications
(99 citation statements)
references
References 13 publications
(25 reference statements)
7
87
1
4
Order By: Relevance
“…The previously reported superior postprandial glucose control of faster insulin aspart compared with standard insulin aspart when administered as a meal bolus during pump or injection therapy in type 1 and type 2 diabetes does not concur with our findings. We observed postprandial glycaemic increments that were comparable after breakfast and even higher with faster insulin aspart after lunch.…”
Section: Discussioncontrasting
confidence: 92%
See 1 more Smart Citation
“…The previously reported superior postprandial glucose control of faster insulin aspart compared with standard insulin aspart when administered as a meal bolus during pump or injection therapy in type 1 and type 2 diabetes does not concur with our findings. We observed postprandial glycaemic increments that were comparable after breakfast and even higher with faster insulin aspart after lunch.…”
Section: Discussioncontrasting
confidence: 92%
“…To our knowledge, this is the first study assessing the incremental benefit of faster insulin aspart during short‐term use of fully closed‐loop insulin delivery in type 2 diabetes. Previous trials that evaluated the use of faster versus standard insulin aspart with injection and pump therapy reported no significant differences for overall glycaemic control between the two insulin formulations . Several factors may explain the lack of improved glucose control during short‐term application of fully closed‐loop despite the more favourable pharmacokinetic and pharmacodynamic profile of faster insulin aspart 2 that has also recently been confirmed in adults with type 2 diabetes .…”
Section: Discussionmentioning
confidence: 98%
“…The recent double‐blind, treat‐to‐target, randomized, 16‐week onset 5 trial evaluated the efficacy and safety of faster aspart administered via CSII in 472 adults with T1D . During the 4‐week run‐in period, participants received reinforcement of training in pump use, diabetes education and explanation of trial procedures; and mean HbA1c decreased from 7.79% and 7.80% in the faster aspart and IAsp treatment arms, respectively, to 7.49% in both arms.…”
Section: Clinical Evidence For Faster Aspartsupporting
confidence: 65%
“…During the treatment period, HbA1c decreased further to 7.44% in the faster aspart arm and to 7.35% in the IAsp arm. As expected with a treat‐to‐target design, non‐inferiority between treatments was confirmed with regard to change in HbA1c; however, the ETD was statistically significant in favour of IAsp (Table ) . In contrast, PPG increments at 30 minutes, 1 and 2 hours after a standardized meal test were statistically significantly reduced with faster aspart compared with IAsp.…”
Section: Clinical Evidence For Faster Aspartmentioning
confidence: 56%
See 1 more Smart Citation